FDA curbs use of antibody drugs sidelined by Omicron
COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they are unlikely to work against the Omicron variant that now accounts for nearly all U.S. infections, U.S. health regulators said Monday.
The U.S. Food and Drug Administration said it was revoking emergency authorization for both drugs, which were purchased by the federal government and given to millions of Americans with COVID-19. If the drugs prove effective against future variants, the FDA said it could reauthorize their use.
The regulatory move was expected because both drugmakers had said the infusion drugs are less able to target Omicron due to its mutations. Still, the federal action could trigger pushback from some Republican governors who have continued promoting the drugs against the advice of health experts.
Omicron's resistance to the two leading monoclonal antibody medicines has upended the treatment playbook for COVID-19 in recent weeks.
Doctors have alternate therapies to battle early COVID-19 cases, including two new antiviral pills from Pfizer and Merck, but both are in short supply. An antibody drug from GlaxoSmithKline that remains effective also is in short supply.
The drugs are laboratory-made versions of virus-blocking antibodies. They are intended to head off severe disease and death by supplying concentrated doses of one or two antibodies early in an infection. Then-U.S. president Donald Trump received Regeneron's antibody combination after he tested positive for the coronavirus in 2020.
The U.S. government temporarily stopped distributing the two drugs in late December, as Omicron was racing across the country to become the dominant variant. But officials resumed distribution after complaints from Republican governors, including Florida's Ron DeSantis, who claimed that the drugs continued to help some Omicron patients.
DeSantis has heavily promoted antibody drugs as a signature part of his administration's COVID-19 response, setting up infusion sites and lauding them at news conferences, while opposing vaccine mandates and other public health measures. Texas Gov. Greg Abbott has also launched state-sponsored infusion sites.
The drugs are not a substitute for vaccination and are generally reserved for people who are the most vulnerable, including seniors, transplant recipients and those with conditions like heart disease and diabetes.
Since early January, the U.S. government has shipped enough doses of the two antibodies to treat more than 300,000 patients.
Both Regeneron and Lilly previously announced they were developing new antibodies that target Omicron.
The move comes days after regulators broadened the use of remdesivir — the first drug approved for COVID-19 — to treat more patients.
On Friday, the FDA expanded the antiviral's approval to include adults and children with early COVID-19 who face a high risk of ending up in the hospital. Remdesivir previously had been limited to hospitalized patients.
An influential panel of federal experts had already recommended using the infused drug to try to head off hospitalization. The same guidelines from the U.S. National Institutes of Health panel recommend against continued use of Lilly and Regeneron's antibody drugs due to their reduced effectiveness against Omicron.
Still, many hospitals will face challenges in ramping up remdesivir treatments. The drug requires three consecutive IV infusions over three days, when used for non-hospitalized patients. That time-consuming process won't be an option for many over-capacity hospitals facing staff shortages.
The FDA made its decision based on a 560-patient study that showed a nearly 90% reduction in hospitalizations when remdesivir is given within seven days of symptoms. The study predates the Omicron variant but, like other antivirals, remdesivir is expected to maintain its performance against the latest variant.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.
COVID-19 COVERAGE
CTVNews.ca Top Stories
LIVE UPDATES | Alberta election live updates: Elections Alberta says it's not experiencing issues
CTV News has declared a number of seats across the province as election results begin to take shape Monday night.

Albertans head to polls in what's expected to be very close election between UCP, NDP
In Alberta today, the United Conservative Party is looking to win a second consecutive majority government while the NDP is fighting to regain the office it lost in 2019.
Singh calling for foreign interference special rapporteur Johnston to step aside
NDP Leader Jagmeet Singh is pushing for special rapporteur David Johnston to 'step aside' from his role examining the issue of foreign interference before he embarks on public hearings.
New Democrat MP says she is target of foreign interference by China
New Democrat MP Jenny Kwan said Monday that Canada's spy agency has confirmed her long-held belief she is being targeted by the Chinese government, as the prime minister granted the NDP's wish to allow more party members to review top-secret intelligence.
Golden Knights reach 2nd Stanley Cup Final after Game 6 win over Stars
William Karlsson, William Carrier and Jonathan Marchessault are finally getting another chance in the Stanley Cup Final, after the first one that came so quick for the Vegas Golden Knights.
Caleb Martin helps Heat to 103-84 Game 7 win over Celtics and spot in NBA Finals
Eastern Conference finals Most Valuable Player Jimmy Butler scored 28 points, and Caleb Martin had 26 points and 10 rebounds to help the eighth-seeded Miami Heat beat the Celtics 103-84 in Game 7 on Monday night and advance to the NBA Finals for the second time in four seasons.
Canadian parliamentarians condemn Uganda's recently passed anti-homosexuality law
Canadian political leaders and parliamentarians are denouncing a new law passed in Uganda that imposes harsh penalties, including the death penalty, for certain cases involving homosexuality.
Free prescription drugs could reduce overall health-care costs in Canada: study
Overall health-care costs could be reduced in Canada by providing free prescription drugs to patients, according to a new study.
Northern B.C., Alberta and all of Ontario under 'high' to 'extreme' wildfire risk: What to know
There's a heightened risk of wildfires across the country during what has been one of the earliest fire seasons on record. From British Columbia to Nova Scotia, here's where the risk is highest.